Pilegaard H, Birk JB, Sacchetti M, Mourtzakis M, Hardie DG, Stewart G, Neufer PD, Saltin B, van Hall G, Wojtaszewski JF (2006). PDH-E1{alpha} Dephosphorylation and Activation in Human Skeletal Muscle During Exercise: Effect of Intralipid Infusion. Diabetes 55:3020-7.

Sacchetti M, Olsen DB, Saltin B & van Hall G. (2005). Heterogeneity in limb fatty acid kinetics in type 2 diabetes. Diabetologia 48, 938-945.

Olsen DB, Sacchetti M, Dela F, Ploug T & Saltin B. (2005). Glucose clearance is higher in arm than leg muscle in type 2 diabetes. Journal of Physiology 565, 555-562.

Hiscock N, Fischer CP, Sacchetti M, van Hall G, Febbraio MA & Pedersen BK. (2005). Recombinant human interleukin-6 infusion during low-intensity exercise does not enhance whole body lipolysis or fat oxidation in humans. American Journal of Physiology- Endocrynology and Metabolims 289, E2-7.

Orngreen MC, Duno M, Ejstrup R, Christensen E, Schwartz M, Sacchetti M & Vissing J. (2005). Fuel utilization in subjects with carnitine palmitoyltransferase 2 gene mutations. Annals of Neurology  57, 60-66.

Sacchetti M, Saltin B, Olsen DB & van Hall G. (2004). High triacylglycerol turnover rate in human skeletal muscle. Journal of Physiology 561, 883-891.

Petersen EW, Carey AL, Sacchetti M, Steinberg GR, Macaulay SL, Febbraio MA & Pedersen BK. (2005). Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. American Journal of Physiology- Endocrynology and Metabolims 288, E155-162.

Orngreen MC, Norgaard MG, Sacchetti M, van Engelen BG & Vissing J. (2004). Fuel utilization in patients with very long-chain acyl-coa dehydrogenase deficiency. Annals of Neurology 56, 279-283.

Febbraio MA, Hiscock N, Sacchetti M, Fischer CP & Pedersen BK. (2004). Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 53, 1643-1648.

Carey AL, Bruce CR, Sacchetti M, Anderson MJ, Olsen DB, Saltin B, Hawley JA & Febbraio MA. (2004). Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with Type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia 47, 1029-1037.

van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P, Hiscock N, Moller K, Saltin B, Febbraio MA & Pedersen BK. (2003). Interleukin-6 stimulates lipolysis and fat oxidation in humans. Journal of  Clinical Endocrinology and Metabolism  88, 3005-3010.

Steensberg A, Fischer CP, Sacchetti M, Keller C, Osada T, Schjerling P, van Hall G, Febbraio MA & Pedersen BK. (2003). Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. Journal of Physiology 548, 631-638.

Sacchetti M, Saltin B, Osada T & van Hall G. (2002). Intramuscular fatty acid metabolism in contracting and non-contracting human skeletal muscle. Journal of Physiology 540, 387-395.

Van Hall G, Bulow J, Sacchetti M, Al Mulla N, Lyngso D & Simonsen L. (2002). Regional fat metabolism in human splanchnic and adipose tissues; the effect of exercise. Journal of Physiology 543, 1033-1046.

van Hall G, Sacchetti M & Radegran G. (2002). Whole body and leg acetate kinetics at rest, during exercise and recovery in humans. Journal of Physiology 542, 263-272.

van Hall G, Sacchetti M, Radegran G & Saltin B. (2002). Human skeletal muscle fatty acid and glycerol metabolism during rest, exercise and recovery. Journal of Physiology 543, 1047-1058.

Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B & Klarlund Pedersen B. (2000). Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. Journal of Physiology 529 Pt 1, 237-242.

van Hall G, Gonzalez-Alonso J, Sacchetti M & Saltin B. (1999). Skeletal muscle substrate metabolism during exercise: methodological considerations. Proceedings of  the Nutrition Society 58, 899-912.